
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is well-positioned to continue their positive growth trajectory with strong performance across all segments, including a 100% economics pass-through structure for their NCI line. Management's proactive decision to exit the exchange market and strategic review of EviCore demonstrates their commitment to driving long-term value for shareholders. With strong leadership, diverse board and workforce, and a solid corporate responsibility platform, Cigna is set to continue its success in the healthcare industry.
Bears say
Cigna Group is expected to have solid performance in its CVS selling season, which should increase overall retention rates and drive new business wins. However, the company's 2026 MLR guidance remains unchanged, indicating potential risks for higher medical costs. Even with a solid start to the 2027 PBS selling season, there are still uncertainties surrounding the company's potential for future growth, particularly with regards to its specialty drug capabilities and exposure to government headwinds.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares